Annamycin

Moleculin Biotech's next-generation anthracycline Annamycin receives WHO approval for the international non-proprietary name "naxtarubicin," marking a significant milestone in its development and potential commercialization.

Newron Pharmaceuticals has received regulatory approval for its ENIGMA-TRS Phase III program evaluating Evenamide as an add-on therapy for treatment-resistant schizophrenia, with patient recruitment beginning immediately.

DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer.

Moleculin Biotech receives FDA feedback allowing a 10% reduction in Phase 3 trial size for AnnAraC, their combination therapy targeting refractory/relapsed Acute Myeloid Leukemia.

Blueprint Medicines projects a $4 billion peak revenue opportunity for its systemic mastocytosis (SM) franchise, driven by AYVAKIT's success and updated SM prevalence estimates.